Standard Contracts
INDEMNIFICATION AGREEMENTIndemnification Agreement • May 31st, 2022 • Alopexx, Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledMay 31st, 2022 Company Industry JurisdictionThis Indemnification Agreement (“Agreement”), dated as of _______, 2022, is by and between Alopexx, Inc., a Delaware corporation (the "Company") and [NAME OF DIRECTOR] (the "Indemnitee").
THE BRIGHAM AND WOMEN'S HOSPITAL, INC. EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • March 7th, 2022 • Alopexx, Inc. • Biological products, (no disgnostic substances) • Massachusetts
Contract Type FiledMarch 7th, 2022 Company Industry JurisdictionThis License Agreement ("Agreement") is made as of the second day of March, 2012 ("Effective Date"), by and between Alopexx Vaccine, LLC, a limited liability company, having a principal place of business at [***] ("Company") and The Brigham and Women's Hospital, Inc., a not-for-profit Massachusetts corporation, with a principal place of business at 75 Francis Street, Boston, Massachusetts 02115 ("Hospital"), each referred to herein individually as a "Party" and collectively as the "Parties".
THE BRIGHAM AND WOMEN’S HOSPITAL, INC. EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • March 7th, 2022 • Alopexx, Inc. • Biological products, (no disgnostic substances) • Massachusetts
Contract Type FiledMarch 7th, 2022 Company Industry JurisdictionThis License Agreement (“AGREEMENT”) is made as of the 4th day of December, 2007 (“EFFECTIVE DATE”), between Alopexx Pharmaceuticals, LLC, a Delaware limited liability company, having a principal place of business at [***](“COMPANY”) and The Brigham and Women’s Hospital, Inc., a not-for-profit Massachusetts corporation, with a principal place of business at 75 Francis Street, Boston, MA 02115 (“HOSPITAL”), each referred to herein individually as a “PARTY” and collectively as the “PARTIES”.
AMENDMENT No. 5 to the EXCLUSIVE PATENT LICENSE AGREEMENT BWH Case No. [***], [***], [***] BWH Agreement No. [***]Exclusive Patent License Agreement • March 7th, 2022 • Alopexx, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledMarch 7th, 2022 Company IndustryThis Amendment No. 5 to the Exclusive Patent License Agreement (“Amendment No. 5”) is effective as of February 2, 2022 (“Amendment No. 5 Effective Date”), by and between The Brigham and Women’s Hospital, Inc., a not-for-profit Massachusetts corporation, with a principal place of business at 75 Francis Street, Boston, Massachusetts 02115 (“Hospital”) and Alopexx, Inc., a Delaware corporation, having a principal place of business at [***] (“Company”), each herein referred to as a “Party” and collectively as the “Parties”. Capitalized terms that are not defined herein shall have the meaning ascribed to them in the License Agreement (as defined below).
COLLABORATION AND LICENSE AGREEMENT (Human Vaccine)Collaboration and License Agreement • September 9th, 2024 • Alopexx, Inc. • Biological products, (no disgnostic substances) • London
Contract Type FiledSeptember 9th, 2024 Company Industry JurisdictionTHIS COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) dated as of September 05, 2024 (the “Effective Date”) is entered into by and between Alopexx, Inc., a Delaware corporation, having a principal place of business at 186 Alewife Brook Parkway #1068, Cambridge, Massachusetts 02138 USA (together with its Affiliates, subsidiaries, successors and permitted assigns, “Alopexx”), and Biotech Consortia, Inc., a Bahamas international business company, having a registered office address at Trident Trust Company (Bahamas) Ltd, 1st Floor, Building A, Caves Corporate Center, Blake Road and West Bay Street, PO Box N-3944, Nassau, Bahamas (together with its Affiliates, subsidiaries, successors and permitted assigns, “BCI”). BCI and Alopexx may be referred to each individually as a “Party” or together collectively as the “Parties.”
AMENDMENT No. 2 to the EXCLUSIVE PATENT LICENSE AGREEMENT BWH Case No. [***], [***], [***], [***] BWH Agreement No. [***]Exclusive Patent License Agreement • March 7th, 2022 • Alopexx, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledMarch 7th, 2022 Company IndustryThis Amendment No. 2 to the Exclusive Patent License Agreement (“Amendment No. 2”) is effective as of February 2, 2022 (“Amendment No. 2 Effective Date”), by and between The Brigham and Women’s Hospital, Inc., a not-for-profit Massachusetts corporation, with a principal place of business at 75 Francis Street, Boston, Massachusetts 02115 (“Hospital”) and Alopexx, Inc., a Delaware corporation, having a principal place of business at 186 Alewife Brook Pkwy #1068 Cambridge, MA 02138 (“Company”), each herein referred to as a “Party” and collectively as the “Parties”. Capitalized terms that are not defined herein shall have the meaning ascribed to them in the License Agreement (as defined below).
Employment AgreementEmployment Agreement • May 31st, 2022 • Alopexx, Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledMay 31st, 2022 Company Industry JurisdictionThis Employment Agreement (the "Agreement") is made and entered into as of _______________, 2022 by and between Thomas Thomas (the "Executive") and Alopexx, Inc., a Delaware corporation (the "Company").